Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 256 AL 270

Depression in Alzheimer's disease. Pathophysiology, diagnosis, and treatment

Modrego PJ.

J Alzheimers Dis. 2010;21(4):1077-87. doi: 10.3233/jad-2010-100153.

Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease

Maher-Edwards G, Zvartau-Hind M, Hunter AJ, Gold M, Hopton G, Jacobs G, Davy M, Williams P.

Curr Alzheimer Res. 2010 Aug;7(5):374-85. doi: 10.2174/156720510791383831.

Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease

Kulkarni PV, Roney CA, Antich PP, Bonte FJ, Raghu AV, Aminabhavi TM.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010 Jan-Feb;2(1):35-47. doi: 10.1002/wnan.59.

Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone

Valen-Sendstad A, Engedal K, Stray-Pedersen B; ADACT Study Group; Strobel C, Barnett L, Meyer N, Nurminemi M.

Am J Geriatr Psychiatry. 2010 Jan;18(1):11-20. doi: 10.1097/JGP.0b013e3181beaaf4.

Management of behavioral problems in Alzheimer's disease

Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C.

Int Psychogeriatr. 2010 May;22(3):346-72. doi: 10.1017/S1041610209991505. Epub 2010 Jan 25.

Dissecting dementia, depression, and drug effects in older adults

Sherrod RA, Collins A, Wynn S, Gragg M.

J Psychosoc Nurs Ment Health Serv. 2010 Jan;48(1):39-47. doi: 10.3928/02793695-20091204-01.

The interactive effect of acute ovarian suppression and the cholinergic system on visuospatial working memory in young women

Craig MC, Brammer M, Maki PM, Fletcher PC, Daly EM, Rymer J, Giampietro V, Picchioni M, Stahl D, Murphy DG.

Psychoneuroendocrinology. 2010 Aug;35(7):987-1000. doi: 10.1016/j.psyneuen.2009.12.012. Epub 2010 Jan 25.

Galantamine for Alzheimer's disease

Prvulovic D, Hampel H, Pantel J.

Expert Opin Drug Metab Toxicol. 2010 Mar;6(3):345-54. doi: 10.1517/17425251003592137.

Follow-up for Alzheimer patients: European Alzheimer Disease Consortium position paper

Nourhashémi F, Olde Rikkert MG, Burns A, Winblad B, Frisoni GB, Fitten J, Vellas B.

J Nutr Health Aging. 2010 Feb;14(2):121-30. doi: 10.1007/s12603-010-0023-z.

Neurochemical basis for symptomatic treatment of Alzheimer's disease

Francis PT, Ramírez MJ, Lai MK.

Neuropharmacology. 2010 Sep-Oct;59(4-5):221-9. doi: 10.1016/j.neuropharm.2010.02.010. Epub 2010 Feb 13.

Adult neurogenesis: a potential tool for early diagnosis in Alzheimer's disease?

Lopez-Toledano MA, Ali Faghihi M, Patel NS, Wahlestedt C.

J Alzheimers Dis. 2010;20(2):395-408. doi: 10.3233/JAD-2010-1388.

Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice

Hayashi Y, Ishida Y, Inoue T, Udagawa M, Takeuchi K, Yoshimuta H, Kiue K, Ninomiya Y, Kawano J, Sameshima T, Kawahara T, Goto I, Shudo K, Kurayama S, Nakamura J, Okahara K, Mitsuyama Y.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 16;34(3):541-5. doi: 10.1016/j.pnpbp.2010.02.016. Epub 2010 Feb 23.

Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease

Cumbo E, Ligori LD.

Epilepsy Behav. 2010 Apr;17(4):461-6. doi: 10.1016/j.yebeh.2010.01.015. Epub 2010 Feb 25.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M.

Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.

Clinical trial efforts in Alzheimer disease: why test statins?

Arvanitakis Z, Knopman DS.

Neurology. 2010 Mar 23;74(12):945-6. doi: 10.1212/WNL.0b013e3181d6479a. Epub 2010 Mar 3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias